Aralez Pharmaceuticals Культура компании

Mr. Adrian Adams has been the Chief Executive Officer of Aralez Pharmaceuticals Inc. (Pozen Inc.) since June 1, 2015 and served as its a consultant from April 2, 2015 to May 31, 2015. Mr. Adams' position as Chief Executive Officer of Pozen, along with his many years of service in the pharmaceutical industry in chief executive positions, enables him to provide important insights regarding the operations of Pozen and the pharmaceutical industry generally, including finance, marketing, strategic planning and senior management personnel matters. Mr. Adams serves as Chief Executive Officer and Director at Aralez Pharmaceuticals Limited. He served as the Chief Executive Officer and President at Auxilium Pharmaceuticals Inc. from December 8, 2011 to January 29, 2015. He served as the Chief Executive Officer of Neurologix Inc. from September 19, 2011 to November 30, 2011. He served as the Chief Executive Officer and President of Inspire Pharmaceuticals, Inc. since February 22, 2010 until May 2011. He served as an Executive Officer of Dainippon Sumitomo Pharma Co., Ltd. until February 2010. Mr. Adams served as the Chief Executive Officer of Sunovion Pharmaceuticals Inc. from May 15, 2007 to February 19, 2010 and served as its President from March 1, 2007 to February 19, 2010. He served as Chief Operating Officer at Sunovion Pharmaceuticals Inc. since March 2007 until May 2007 and served as its Executive Director since March 2007 until February 19, 2010. Mr. Adams served as the Chief Operating Officer of Sepracor, Inc. from March 2007 to May 2007. He served as an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. until February 2010. Mr. Adams served as the Chief Executive Officer of KOS Pharmaceuticals Inc., from January 1, 2002 to December 2006 and served as its President and Chief Operating Officer from April 26, 2001 to December 2006. Mr. Adams served as the President and Chief Executive Officer of Novartis Pharmaceuticals UK from 1999 to 2001. Mr. Adams served at SmithKline Beecham Pharmaceuticals from 1992 to 1999 in various capacities, including President and Chief Executive Officer of Canadian subsidiaries. Mr. Adams's assignments at SmithKline Beecham included Vice President and Director of Worldwide Marketing in the US and Director and Vice President of Sales and Marketing in the United Kingdom. He is a highly qualified pharmaceutical executive who has successfully led the growth and corporate development of two publicly traded companies. He has strong skills in commercialization, business development and global partnerships, including experience in licensing and developing respiratory products and an excellent understanding of the evolving specialty pharmaceutical market. Mr. Adams began his career at ICI Pharmaceuticals, where he rose from Research Laboratory Assistant to Director of Sales and Marketing. During his career he has worked in most therapeutic areas and has been instrumental in a number of major global and national product launches including Paxil, Famvir, Coreg, Diovan, Tenormin and Zestril. Mr. Adams has over 30 years of experience in pharmaceutical executive leadership with a record of successfully building organizations, delivering successful results against short, medium and long-term goals and creating shareholder value. Mr. Adams has over 30 years of experience in both specialty and large pharmaceutical organizations. Having spent his entire career in the pharmaceutical industry, Mr. Adams has a broad background encompassing research, sales, marketing, international and national product management, business development, general management and he has extensive senior management experience. He has been the Chairman of AcelRx Pharmaceuticals, Inc. since February 2013. He served as the Chairman of Neurologix Inc. from September 19, 2011 to November 30, 2011. He served as the Chairman of Arisaph Pharmaceuticals, Inc. since 2005 and served as its Director. He has been a Director of POZEN Inc. since June 1, 2015. Mr. Adams serves as a Director of PhRMA. He has been a Director of AcelRx Pharmaceuticals, Inc. since February 11, 2013. He served as a Director of Amylin Pharmaceuticals, LLC from October 2007 to August 2012. He served as a Director of Auxilium Pharmaceuticals Inc. from December 7th, 2011 to January 29, 2015. He served as a Director at Inspire Pharmaceuticals, Inc. since February 22, 2010. He served as an Executive Director of Sepracor, Inc. from March 2007 to February 19, 2010. He served as a Director of KOS Pharmaceuticals Inc. from January 01, 2002 to December 2006. He served as Director at Neurocrine Biosciences Inc. from December 5, 2005 to February 20, 2007. He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree. Mr. Adams graduated from the Royal Institute of Chemistry at Salford University in the U.K.

Mr. Andrew I. Koven has been the President and Chief Business Officer at Aralez Pharmaceuticals Inc. (Pozen Inc.) since June 1, 2015. Mr. Koven served as General Counsel, Chief Administrative Officer, Executive Vice President and Secretary of Auxilium Pharmaceuticals Inc. from February 3, 2012 to January 29, 2015. He served as an Executive Vice President, Secretary and General Counsel at Sunovion Pharmaceuticals Inc. since March 1, 2007. Mr. Koven served as the President and Chief Administrative Officer of Neurologix Inc. from September 19, 2011 to November 30, 2011. Mr. Koven was responsible for legal, intellectual property, corporate development and licensing, legal, human resources and general daily operations. He has more than 26 years of experience practicing law, with over 18 years of experience in the pharmaceutical industry, including over ten years of pharmaceutical industry experience in both the private and public sector. He served as the Chief Administrative & Legal Officer and Executive Vice President at Inspire Pharmaceuticals, Inc. since May 10, 2010. He had been responsible for the legal, intellectual property, CD&L and compliance departments. Mr. Koven served as an Executive Vice President, General Counsel and Secretary of Sepracor, Inc. from March 1, 2007 to 2010. He was responsible for Sepracor's legal and government affairs and compliance departments and the corporate secretarial function. During his time at Sepracor, he was significantly involved with all CD&L and merger and acquisition activities and managed intellectual property, employment, regulatory, corporate governance, litigation, compliance, commercial transactions and sales and marketing policies and procedures. Mr. Koven served as Secretary, General Counsel, Senior Vice President and Executive Vice President of Kos Pharmaceuticals, Inc. from October 7, 2003 to 2007. He oversaw all of Kos Pharmaceuticals, Inc.'s legal affairs, including General Administrative, Transactional and Intellectual Property Matters. Prior to that, he held a series of high-level positions with Warner-Lambert, culminating with his role as Assistant General Counsel of Pharmaceuticals in North America and Assistant General Counsel, Consumer Healthcare N.A. from 1993 to 2000 and managed all legal aspects of Kos Pharmaceuticals, Inc.'s North American pharmaceutical business, including the negotiation and drafting of option and licensing agreements, joint venture transactions and acquisitions. Mr. Koven served as Senior Vice President and Chief Legal Officer of Lavipharm Laboratories, Inc. since 2000 and served as its General Counsel. Previously, he served as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. He worked with Cahill, Gordon and Reindel in New York. He has been a Director of Kala Pharmaceuticals, Inc. since October 2, 2017. He served as a Director of Neurologix Inc. since September 20, 2011 until November 30, 2011. He served as Counsel, Corporate and Investment Division for the Equitable Life Assurance Society of the United States and as a Corporate Associate in the law firm of Cahill Gordon & Reindell in New York City. Mr. Koven received a B.A. in Political Science from Dalhousie University and a LL.B. from Dalhousie University Law School in Halifax, Nova Scotia Canada and a LL.M. from Columbia University Law School in New York City.

Jennifer Armstrong serves as the Executive Vice President, Human Resources and Administration of Aralez Pharmaceuticals Inc.. Jennifer started at Aralez Pharmaceuticals Inc. in June of 2015. Jennifer currently resides in Greater Philadelphia Area.

Sanjay Subramanian serves as the VP Finance of Aralez Pharmaceuticals Inc.. Sanjay started at Aralez Pharmaceuticals Inc. in October of 2015. Sanjay currently resides in Greater New York City Area.

Chris Boneham serves as the Executive Director, Managed Markets of Aralez Pharmaceuticals Inc.. Chris started at Aralez Pharmaceuticals Inc. in July of 2015. Chris currently resides in Raleigh-Durham, North Carolina Area.

Jim Elliott serves as the Executive Director, Sales Learning and Development of Aralez Pharmaceuticals Inc.. Jim started at Aralez Pharmaceuticals Inc. in October of 2015. Jim currently resides in Greater Philadelphia Area.

Ashley Ivanowicz serves as the Director, Human Resources of Aralez Pharmaceuticals Inc.. Ashley started at Aralez Pharmaceuticals Inc. in March of 2018. Ashley currently resides in Greater Philadelphia Area.

Larry Shewmake serves as the Key Account Director of Aralez Pharmaceuticals Inc.. Larry started at Aralez Pharmaceuticals Inc. in November of 2016. Larry currently resides in Greater Minneapolis-St. Paul Area.

Mike Kaseta serves as the Chief Financial Officer of Aralez Pharmaceuticals Inc.. Mike started at Aralez Pharmaceuticals Inc. in March of 2018. Mike currently resides in Greater New York City Area.